NEW YORK (GenomeWeb News) — General Electric late yesterday said it plans to acquire two of Abbott Technologies’ diagnostics businesses for $8.13 billion in cash, and will leave alone the company’s molecular diagnostic unit.
 
The acquisition includes Abbott’s in vitro diagnostics and point-of-care divisions and represents another rung in GE Healthcare’s goal of creating a business that combines in vitro and in vivo technologies to diagnose diseases.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.